Henrik Junger, Birgit Knoppke, Kilian Weigand, Katja Evert, Frank W. Brennfleck, Michael Melter, Hans J. Schlitt, Stefan M. Brunner – 17 February 2020
Alessandro Vitale, Franco Trevisani, Fabio Farinati, Umberto Cillo – 16 February 2020 – Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhosis and additional comorbidities. The “stage hierarchy” approach, which involves linking each stage (or substage) of the disease to a specific treatment, has become the main proposed treatment strategy for the clinical management of HCC, particularly in the West.
Akanksha Sharma, Alok K. Verma, Matthew Kofron, Ramesh Kudira, Alexander Miethke, Tong Wu, Jiang Wang, Chandrashekhar R. Gandhi – 16 February 2020
Nikhil Kapila, Asad Ur Rahman, Xaralambos B. Zervos – 16 February 2020
Alessandro Vitale, Franco Trevisani, Fabio Farinati, Umberto Cillo – 16 February 2020 – Treatment allocation is extremely complex in patients with hepatocellular carcinoma (HCC) because this neoplasm arises, in most cases, in patients with cirrhosis and additional comorbidities. The “stage hierarchy” approach, which involves linking each stage (or substage) of the disease to a specific treatment, has become the main proposed treatment strategy for the clinical management of HCC, particularly in the West.
Philippe Roingeard, Elodie Beaumont – 15 February 2020
Tingting Su, Yasuko Iwakiri – 15 February 2020
Ekaterina Smirnova, Puneet Puri, Mark D. Muthiah, Kalyani Daitya, Robert Brown, Naga Chalasani, Suthat Liangpunsakul, Vijay H. Shah, Kayla Gelow, Mohammed S. Siddiqui, Sherry Boyett, Faridoddin Mirshahi, Masoumeh Sikaroodi, Patrick Gillevet, Arun J. Sanyal – 14 February 2020
Johann Felden, Augusto Villanueva – 14 February 2020 – Patient selection and organ allocation for liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) relies predominantly on clinical parameters, such as tumor burden (ie, radiological imaging). Patients transplanted within Milan criteria have outstanding outcomes with a 5‐ and 10‐year survival of 70% and 55%, respectively. Tumor recurrence after transplantion is rare in these patients (10%); however, treatment options upon recurrence are generally limited, and outcomes are poor.
Hyo Jung Park, Kyoung Won Kim, Jae Hyun Kwon, Jeongjin Lee, Taeyong Park, Heon‐Ju Kwon, Gi‐Won Song, Sung‐Gyu Lee – 14 February 2020 – The spatial variability of hepatic fat reduction in potential living liver donors with hepatic steatosis (HS) who undergo lifestyle modification has not been investigated. Here, we aimed to examine the intrasegmental and intersegmental variability of changes in liver attenuation on computed tomography (CT) in potential living liver donors with HS after diet modification and exercise.